Kate Haviland, MBA

• Former President and CEO of Blueprint Medicines

• Previously served as Chief Operating Officer and Chief Business Officer of Blueprint Medicines

• Played a central role in Blueprint’s transformation from a discovery-stage organization into a fully integrated commercial enterprise

• Board member of Bicara Therapeutics; Chair of Fulcrum Therapeutics

• MBA from Harvard Business School; B.A. in Biochemistry/Molecular Biology and Economics from Wesleyan University